Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Feb;13(1):66-70.
doi: 10.1007/s10147-007-0733-3. Epub 2008 Feb 29.

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

Magnus Rizell  1 , Mats Andersson, Christian Cahlin, Larsolof Hafström, Michael Olausson, Per Lindnér
Affiliations
Clinical Trial

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

Magnus Rizell et al. Int J Clin Oncol. 2008 Feb.

Abstract

Background: Hepatocellular cancer (HCC), as well as cholangiocellular cancer (CCC), has an extremely poor prognosis due to the extent of tumor at diagnosis and the underlying liver disease. Sirolimus is used in the transplantation setting as an immunosuppressive agent, but it also possesses antiproliferative and antiangiogenic properties. The objective of the study was to evaluate the effect of sirolimus on HCC and CCC.

Methods: In a prospective single-arm protocol, the tumor response to sirolimus as the primary endpoint was studied in 21 patients with advanced HCC and nine with CCC. Sirolimus was administered once daily by mouth, with the dose adjusted to a serum trough level between 4 and 15 mug/ml. Tumor response was evaluated by computed tomography (CT) or magnetic resonance imaging (MRI), according to the Response Evaluation Criteria in Solid Tumors (RECIST), every third month. Secondary measures were overall survival, time to tumor progression, tumor markers, and side effects.

Results: Of the patients with HCC, one had partial remission (PR) and fi ve patients had stable disease (SD) at 3 months. Of the patients with CCC, three had SD. The median survival for patients with HCC was 6.5 months (range, 0.2-36 months) and that for patients with CCC was 7 months (range, 2.6-35 months).

Conclusion: Treatment of HCC and CCC with sirolimus can induce temporary PD or SD. This pilot study indicates that sirolimus might be a promising drug for this treatment, but further clinical studies elucidating the biological effects are advocated.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Liver Transpl. 2004 Oct;10(10):1301-11 - PubMed
    1. Transpl Int. 2005 Jan;18(1):89-94 - PubMed
    1. Liver Transpl. 2001 Jun;7(6):473-84 - PubMed
    1. Oncogene. 2006 Jun 26;25(27):3818-22 - PubMed
    1. Anticancer Res. 2005 Mar-Apr;25(2A):789-93 - PubMed

Publication types

MeSH terms

LinkOut - more resources

-